This present review provides an overview of Acetylsalicylic Acid (ASA), emphasizing its role in cardiovascular disease prevention. ASA’s mechanism involves irreversible inhibition of COX activity, impacting prostaglandin synthesis. The ASA as a crucial lifelong therapy for cardiovascular events, with over 50 million Americans using it. While its clinical benefits are established, the underlying mechanisms, especially in coronary artery disease (CAD) secondary prevention, lack full clarity. The document discusses pharmacokinetics, pharmacodynamics, and optimal doses, including ongoing studies like ADAPTABLE to determine the most effective dosage for secondary prevention. It also touches on pharmacogenomics, highlighting genetic variations influencing ASA response and metabolism, particularly in genes like CYP2C9, UGT1A6, and TBXA2R. Conclusion: The review aims to consolidate information on pharmacological, molecular, genetic, and clinical aspects of ASA’s protective effects in CAD. The expression and saturation of enzymes involved in ASA metabolism can alter individual responses, so understanding the pharmacogenomic profile is important for personalizing treatment and improving clinical outcomes.
OscarssonAGuptaAFredriksonM, et al.To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. Br J Anaesth. 2010;104(3):305–312.
2.
GersteinNSSchulmanPMGersteinWH, et al.Should more patients continue aspirin therapy perioperatively? Clinical impact of aspirin withdrawal syndrome. Ann Surg2012; 255(5): 811–819.
3.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ2002; 324(7329): 7186. https://www.ctsu.ox.ac.uk
PatronoCGarcía RodríguezLALandolfiR, et al.Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med2005; 353(22): 2373–2383.
8.
BogatchevaNVSergeevaMGDudekSM, et al.Arachidonic acid cascade in endothelial pathobiology. Microvasc Res2005; 69: 107–127. https://pubmed.ncbi.nlm.nih.gov/15896353/
9.
Ruiz MoriE. Antiagregantes plaquetarios. Revista Peruana de Cardiología2006; XXXII(1): 29–38.
10.
ClàriaJRomanoM. Pharmacological intervention of cyclooxygenase-2 and 5-lipoxygenase pathways. Impact on inflammation and cancer. Curr Pharmaceut Des2005; 11(26): 3431–3447. https://pubmed.ncbi.nlm.nih.gov/16250846/
11.
FitzGeraldGA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov2003; 2(11): 879–890. https://pubmed.ncbi.nlm.nih.gov/14668809/
PatronoCCollerBFitzGeraldGA, et al.Platelet-active drugs: the relationships among dose, effectiveness, and side effects - the seventh ACCP conference on antithrombotic and thrombolytic therapy. In: Chest. Northbrook, IL: American College of Chest Physicians, 2004, 234S. https://pubmed.ncbi.nlm.nih.gov/15383474/
14.
LollPJPicotDGaravitoRM. The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin h2 synthase. Nat Struct Biol1995; 2(8): 637–643. https://pubmed.ncbi.nlm.nih.gov/7552725/
15.
RowlinsonSWKieferJRPrusakiewiczJJ, et al.A novel mechanism of cyclooxygenase-2 inhibition involving interactions with ser-530 and tyr-385. J Biol Chem2003; 278(46): 45763–45769. https://pubmed.ncbi.nlm.nih.gov/12925531/
16.
HochgesangGPRowlinsonSWMarnettLJ. Tyrosine-385 is critical for acetylation of cyclooxygenase-2 by aspirin. J Am Chem Soc2000; 122: 6514–6515. DOI: 10.1021/ja0003932.
17.
ToscoPLazzaratoL. Mechanistic insights into cyclooxygenase irreversible inactivation by aspirin. ChemMedChem2009; 4(6): 939–945. DOI: 10.1002/cmdc.200800438.
PedersenAKFitzGeraldGA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med1984; 311(19): 1206–1211. DOI: 10.1056/NEJM198411083111902.
20.
ClarkeRJMayoGPriceP, et al.Suppression of thromboxane A 2 but not of systemic Prostacyclin by controlled-release aspirin. N Engl J Med1991; 325(16): 1137–1141. https://pubmed.ncbi.nlm.nih.gov/1891022/
21.
RothGJMajerusPW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest1975; 56(3): 624–632. https://pmc/articles/PMC301910/?report=abstract
22.
RothGJStanfordNMajerusPW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA1975; 72(8): 3073–3076. https://pubmed.ncbi.nlm.nih.gov/810797/
23.
DemersLMBudinREShaikhBS. The effects of aspirin on megakaryocyte prostaglandin production. Proc Soc Exp Biol Med1980; 163(1): 24–29. https://pubmed.ncbi.nlm.nih.gov/6766214/
TaylorMLMissoNLAStewartGA, et al.The effects of varying doses of aspirin on human platelet activation induced by PAF, collagen and arachidonic acid. J clin Pharmac1992; 33: 25–31.
27.
WeitzJI. Coagulación de la sangre y anticoagulantes, fibrinolíticos y antiplaquetarios. In: Goodman & Gilman, la base farmacológica de la terapéutica. New York, NY: McGraw-Hill Medical, 2011, 12, 848–876.
28.
BradlowBAChettyNF. Dosage frequency for suppression of platelet function by low dose aspirin therapy. Thromb Res1982; 27: 99–110.
29.
ColemanJLAlbertsMJ. Effect of aspirin dose, preparation, and withdrawal on platelet response in normal volunteers. Am J Cardiol2006; 98(6): 838–841.
PatrignaniPFilabozziPPatronoC. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest1982; 69(6): 1366–1372. https://pubmed.ncbi.nlm.nih.gov/7045161/
32.
GrosserTFriesSFitzGeraldGA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest2006; 116(1): 4–15. https://pmc/articles/PMC1323269/?report=abstract
BenigniAGregoriniGFruscaT, et al.Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med1989; 321(6): 357–362.
37.
DuttaSKumarSHyettJ, et al.Molecular targets of aspirin and prevention of preeclampsia and their potential association with circulating extracellular vesicles during pregnancy. Int J Mol Sci. MDPI AG2019; 20. https://pmc/articles/PMC6769718/?report=abstract
38.
FernandesMAGerardiMCAndreoliL, et al.Management of maternal antiphospholipid syndrome. Clin Exp Rheumatol2020; 38(1): 149–156. https://pubmed.ncbi.nlm.nih.gov/31287415/
RothwellPMCookNRGazianoJM, et al.Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet2018; 392(10145): 387–399.
41.
Singh RangerG. The role of aspirin in colorectal cancer chemoprevention. Crit Rev Oncol Hematol2016; 104: 87–90, Elsevier Ireland Ltd.
42.
YeSLeeMLeeD, et al.Association of long-term use of low-dose aspirin as chemoprevention with risk of lung cancer. JAMA Netw Open2019; 2(3): e190185.
ASCEND Study Collaborative GroupBowmanLMafhamMWallendszusK, et al.Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med2018; 379(16): 1529–1539. DOI: 10.1056/NEJMoa1804988.
45.
CollinsRPetoRHennekensC, et al.Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet2009; 373(9678): 1849. https://www.thelancet.com
46.
GazianoJMBrotonsCCoppolecchiaR, et al.Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet2018; 392(10152): 1036–1046. https://pmc/articles/PMC7255888/?report=abstract
47.
BugiardiniRPavasovićSYoonJ, et al.Aspirin for primary prevention of ST segment elevation myocardial infarction in persons with diabetes and multiple risk factors. EClinicalMedicine2020; 27: 100548. https://pubmed.ncbi.nlm.nih.gov/33150322/
48.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ1994; 308(6921): 81–106.
SmithSCBenjaminEJBonowRO, et al.AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation2011; 124: 2458–2473, Lippincott Williams and Wilkins. https://pubmed.ncbi.nlm.nih.gov/22052934/
51.
PetersRJGMehtaSRFoxKAA, et al.Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation2003; 108(14): 1682–1687. https://pubmed.ncbi.nlm.nih.gov/14504182/
52.
AronowHDCaliffRMHarringtonRA, et al.Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO trial). Am J Cardiol2008; 102(10): 1285–1290. https://pubmed.ncbi.nlm.nih.gov/18993142/
53.
ChoiCKKimNChoiJW, et al.Effect of low-dose, enteric coated aspirin on gastrointestinal bleeding in patients with coronary artery disease. Gut Liver2008; 2(2): 99–104. https://pubmed.ncbi.nlm.nih.gov/20485618/
54.
LeeMCryerBFeldmanM. Dose effects of aspirin on gastric prostaglandins and stomach mucosal injury. Ann Intern Med1994; 120(3): 184–189. https://pubmed.ncbi.nlm.nih.gov/8273981/
55.
HallHMDe LemosJAEnriquezJR, et al.Contemporary patterns of discharge aspirin dosing after acute myocardial infarction in the United States results from the national cardiovascular data registry (NCDR). Circ Cardiovasc Qual Outcomes2014; 7(5): 701–707. https://pubmed.ncbi.nlm.nih.gov/25116897/
56.
JohnstonAJonesWSHernandezAF. The adaptable trial and aspirin dosing in secondary prevention for patients with coronary artery disease. Curr Cardiol Rep2016; 18: 1–9. Current Medicine Group LLC 1. https://link.springer.com/article/10.1007/s11886-016-0749-2
YiannakopoulouE. Pharmacogenomics of acetylsalicylic acid and other nonsteroidal anti-inflammatory agents: clinical implications. Eur J Clin Pharmacol2013; 69(7): 1369–1373. https://pubmed.ncbi.nlm.nih.gov/23435614/
60.
PengLLZhaoYQZhouZY, et al.Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. Acta Pharmacol Sin2016; 37(11): 1442–1448. https://pubmed.ncbi.nlm.nih.gov/27641736/
61.
PostulaMKaplon-CieslickaARosiakM, et al.Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes. J Thromb Haemostasis2011; 9(11): 2291–2301.
62.
EbrahimiPFarhadiZBehzadifarM, et al.Prevalence rate of laboratory defined aspirin resistance in cardiovascular disease patients: a systematic review and meta-analysis. Caspian J Intern Med2020; 11: 124–134, Babol University of Medical Sciences.
63.
Santos-GallegoCGBadimonJ. Overview of aspirin and platelet biology. Am J Cardiol2021; 144: S2–S9.
64.
WiśniewskiAFilipskaKSikoraJ, et al.Aspirin resistance affects medium-term recurrent vascular events after cerebrovascular incidents: a three-year follow-up study. Brain Sci2020; 10(3): 179.
GumPAKottke-MarchantKPoggioED, et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease.
67.
PasebanMMarjanehRMBanachM, et al.Modulation of microRNAs by aspirin in cardiovascular disease. Trends Cardiovasc Med2020; 30: 249–254, Elsevier Inc.
68.
FerreiraMFreitas-SilvaMAssisJ, et al.The emergent phenomenon of aspirin resistance: insights from genetic association studies. Pharmacogenomics2020; 21: 125–140, Future Medicine Ltd.
69.
GoodmanTFerroASharmaP. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol2008; 66: 222–232, Blackwell Publishing Ltd.
GrosserTFriesSLawsonJA, et al.Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin. Circulation2013; 127(3): 377–385.
72.
FeherGKoltaiKPappE, et al.Aspirin resistance possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables background and objective: recent studies have described the incidence. Drugs Aging2006; 23: 559.
73.
PulcinelliFMPignatelliPCelestiniA, et al.Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol2004; 43(6): 979–984.
74.
RoccaBSantilliFPitoccoD, et al.The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemostasis2012; 10(7): 1220–1230.
75.
ErtugrulDTTutalEYildizM, et al.Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. J Clin Endocrinol Metab2010; 95(6): 2897–2901.
76.
KuliczkowskiWWitkowskiAPolonskiL, et al.Interindividual variability in the response to oral antiplatelet drugs: a position paper of the working group on antiplatelet drugs resistance appointed by the section of cardiovascular interventions of the polish cardiac society, endorsed by the working group on thrombosis of the European society of Cardiology. Eur Heart J2009; 30: 426–435, Oxford University Press.
